Emend
(aprepitant)ApprovedSmall molecule
Aprepitant is used to prevent nausea and vomiting caused by chemotherapy and surgery. It works by blocking signals in the brain that trigger these uncomfortable side effects.[2] Emend is currently approved and in use across 33 indications[4].[1]
Emend is one of 701 small molecule programs targeting Glioma. It is currently in Approved.
33
Indications
122
Total Trials
7
Active Trials
700
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
15
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 29 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Voltaren
NovartisPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nausea and vomiting39 trials
Show 36 more trials
Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries
Completed·—·Phase 2/3·NCT02525848·150 enrolled
"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
Completed·—·Phase 3·NCT03219710·240 enrolled
Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery
Not yet recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 4·NCT07371728·100 enrolled
Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Completed·—·N/A·NCT00717054·115 enrolled
The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting
Unknown status·—·Phase 4·NCT05772676·400 enrolled
Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents
Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 3·NCT05346731·210 enrolled
Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Completed·—·N/A·NCT00659737·115 enrolled
Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery
Unknown status·—·Phase 4·NCT05632224·60 enrolled
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Not yet recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 3·NCT06543966·486 enrolled
Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients
Recruiting·—·Phase 3·NCT07248280·260 enrolled
Chemotherapy-induced nausea and vomiting7 trials
Show 4 more trials
Major Depressive Disorder5 trials
Nausea5 trials
Chemotherapy4 trials
Show 1 more trial
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Completed·—·Phase 3·NCT01402024·96 enrolled
47 more indications
Pruritus4 trials
Aprepitant in the Management of Biological Therapies-related Severe Pruritus
Completed·—·Phase 2·NCT01683552·45 enrolled
Breast Cancer3 trials
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05841849·1,028 enrolled
Treatment3 trials
Prophylaxis2 trials
Non-Small Cell Lung Cancer2 trials
Withdrawal2 trials
Ondansetron2 trials
Lung Cancer2 trials
Tics2 trials
PrEP2 trials
Gastric Emptying1 trial
Carcinoma1 trial
Lymphoma1 trial
PTSD Symptoms1 trial
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD
Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 2·NCT00896038·58 enrolled
Advanced Cancer1 trial
Autologous Hematopoietic Stem Cell Transplantation1 trial
Induction Chemotherapy1 trial
Adolescent1 trial
Enhanced Recovery1 trial
Ovarian Cancer1 trial
Pancreatitis1 trial
A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Completed·—·N/A·NCT00736073·73 enrolled
Acute Myeloid Leukemia1 trial
Carboplatin1 trial
Low Dose Aprepitant for Patients Receiving Carboplatin
Terminated·—·Phase 2·NCT03237611·15 enrolled
Pediatric1 trial
Glioma1 trial
Headache1 trial
Glioblastoma1 trial
TIA1 trial
Differentiating the Effects of Substance P and Beta-endorphin
Completed·—·N/A·NCT01854177·10 enrolled
ESS1 trial
The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing
Completed·—·N/A·NCT01580423·16 enrolled
Malignant Tumor1 trial
Adult1 trial
Cancer1 trial
Regulatory
FDA Approval Timeline[5]
Jun 30, 2006
EMEND
NDA NDA021549
Dec 17, 2015
EMEND
NDA NDA207865
Nov 9, 2017
CINVANTI
NDA NDA209296
Sep 16, 2022
APONVIE
NDA NDA216457
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Emend drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for aprepitant. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Emend. U.S. Food & Drug Administration.
- [7]